Pathios Therapeutics

Pathios Therapeutics are world-leading experts with unique expertise in GPCR drug development, focused on GPR65 as a high-value immunology target with robust genetic links to multiple human diseases. Our clinical-stage oncology programme leverages cutting-edge proprietary genetic insights, transcriptomics, and functional immunology of GPR65 as a key immune cell sensor of acidosis in multiple pathological environments, to bring about a revolutionary new approach to treating a broad spectrum of cancers. We are also building an emerging pipeline in neuroinflammatory and neurodegenerative disorders leveraging the broader immunological roles of this receptor in cell types such as microglia. Based in in Oxford, UK, Pathios combines a team of experienced scientific leaders with strategic external partnerships. We are supported by top tier investors Canaan, Brandon Capital Partners and Bristol Myers Squibb. Pathios is part of the M:M Bio ecosystem, which integrates experienced drug discovery expertise with stage-appropriate, agile, operational infrastructure that results in companies that are efficient, cost effective, focused and great places to work.